PRMT5 and cancer: Studies to understand mechanisms by which PRMT5 overexpression may cooperate with recurrent genomic lesions to contribute to CLL pathogenesis and progression are also necessary as the critical targets for response to PRMT5 inhibition are likely context-dependent for each cancer type54.